About NeuClone

NeuClone is specializing in the production of recombinant proteins using mammalian cell culture technology. The initial focus of the firm's business activity is the generation of a broad range of Chinese hamster ovary (CHO) cell lines engineered to produce biogeneric drugs with substantially enhanced productivity and biological activity.

The CHO cell line is the leading platform for the production of complex therapeutic proteins which include monoclonal antibodies. A number of factors contribute to successful commercial production of biopharmaceuticals in CHO cells such as growth in suspension and serum-free media. The impeccable lineage of NeuClone's superior CHO cell lines is a distinguishing feature of the company's production platform. NeuClone's recombinant CHO cell lines are generated according to the highest safety standards stipulated by the US Food and Drug Administration Guidance for Industry.

A highly effective gene expression system

NeuClone has developed a highly effective gene expression system which maximizes the levels of recombinant protein biosynthesis and secretion in CHO cells. Expression of recombinant protein is achieved using the company's proprietary expression vectors encoding the desired gene of interest. A controlled selection of the clonal isolates containing the integrated DNA results in increased expression of the desired gene product in our recombinant CHO cell lines.

Process Development and Technology Transfer

NeuClone aims to provide superior CHO cell lines with exceptional growth and production characteristics. The company is relentless in its efforts to achieve the highest standards in its production cell lines without compromising growth and stability. NeuClone offers to its clients a process development program through media optimisation and a purification strategy ready for technology transfer to the Client's facilities. Please contact us for your specific requirements.